At present, B cell maturation antigen (BCMA) is the most successful target used for CAR-T cell therapy in MM, and anti-BCMA CAR-T cell therapy has achieved unprecedented responses in R/R MM patients and brought new hope for these R/R MM patients (3–7). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.